Borrelia antigen
AssigneeSymbicom Aktiebolag
InventorsSven Bergstrom, Alan G. Barbour, Louis A. Magnarelli
Life of this patent
Estimating the term…
Abstract
Disclosed and claimed are: substantially pure lipidated OspA protein, compositions containing substantially pure lipidated OspA protein, immunogenic fragments of OspA, compositions containing immunogenic fragments of OspA, polypeptides containing an immunogenic fragment or epitopic region of OspA, and methods for making and using such proteins, fragments, and polypeptides.
Claims23
An immunological composition comprising:
- an immunogenic fragment of substantially pure OspA;
- and an immunologically acceptable carrier or vehicle.
Substantially pure immunogenic fragment of OspA.
A method of producing a vaccine containing a substantially pure lipidated OspA protein comprising recovering the OspA protein from a host organism transformed with a vector containing DNA encoding the OspA protein and admixing the OspA protein with an immunologially acceptable carrier or vehicle.
An immunological composition comprising substantially pure lipidated OspA from two or more strains of Borrelia burgdorferi and an immunologically acceptable carrier or vehicle.
An immunological composition comprising:
- a polypeptide and an immunologically acceptable carrier or vehicle;
- wherein the polypeptide consists essentially of an immunogenic fragment of OspA.
A polypeptide consisting essentially of an immunogenic fragment of OspA.
A method of producing an immunological composition containing a substantially pure immunogenic fragment of OspA protein or a polypeptide consisting essentially of an immunogenic fragment of OspA comprising recovering the OspA protein fragment or polypeptide from a host organism transformed with a vector containing DNA encoding the OspA protein fragment or the polypeptide, and admixing the OspA protein fragment or the polypeptide with an immunologially acceptable carrier or vehicle.
An immunological composition comprising substantially pure immunogenic fragments of OspA from two or more strains of Borrelia burgdorferi and an immunologically acceptable carrier or vehicle.
An immunological composition comprising:
- a polypeptide and an immunologically acceptable carrier or vehicle;
- wherein the polypeptide consists essentially of an epitopic region of OspA.
A polypeptide consisting essentially of an epitopic region of OspA.
An immunological composition comprising a first polypeptide, a second polypeptide, and an immunologically acceptable carrier or vehicle;
- wherein the first polypeptide consists essentially of a first epitopic region or a first immunogenic fragment of OspA, the second polypeptide consists essentially of a second epitopic region or a second immunogenic fragment of OspA;
- and, the first epitopic region or first immunogenic fragment is different than the second epitopic region or second immunogenic fragment, or the first epitopic region or first immunogenic fragment and the second epitopic region or second immunogenic fragment are from different strains of Borrelia burgdorferi.
A vaccine comprising substantially pure, lipidated OspA.
Substantially pure lipidated OspA.
Dependencies are inferred from the claim text.